Shannon Hall
Adult Health · Birmingham, ALNPI 1417310921
Payments from drug & device makers
Across 139 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$543
- Pfizer$306
- Lilly USA, LLC$226
- Novo Nordisk$168
- Neurocrine Biosciences, Inc.$129
- GSK$123
- plus $829 from 15 others
What the payments were for
- Food & beverage$2,323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $543 |
| Pfizer | 18 | $306 |
| Lilly USA, LLC | 15 | $226 |
| Novo Nordisk | 8 | $168 |
| Neurocrine Biosciences, Inc. | 4 | $129 |
| GSK | 5 | $123 |
| Ardelyx, Inc. | 5 | $112 |
| Amgen | 7 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Corium, LLC | 5 | $92 |
| AstraZeneca | 4 | $69 |
| Ironwood Pharmaceuticals, Inc | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Antares Pharma, Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $35 |
| Halozyme Inc | 1 | $34 |
| Shield Therapeutics Inc | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
How this compares
$2,323 in reported general payments places this provider in the 75th percentile of 308 adult health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 104 | $109,685 |
| MounjaroTirzepatide | 52 | $58,629 |
| OtezlaApremilast | 11 | $55,237 |
| JardianceEmpagliflozin | 68 | $48,545 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $45,163 |
| EliquisApixaban | 36 | $26,774 |
| LinzessLinaclotide | 35 | $18,793 |
| CreonLipase/Protease/Amylase | 12 | $13,163 |
| FarxigaDapagliflozin Propanediol | 18 | $10,446 |
| Repatha SureclickEvolocumab | 13 | $9,496 |
| Aripiprazole | 71 | $5,443 |
| MovantikNaloxegol Oxalate | 13 | $5,440 |
| Galantamine Hbr | 38 | $3,183 |
| Risedronate Sodium | 12 | $2,961 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 82 | $2,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $168 | $109,685104 claims |
| Lilly USA, LLCMounjaro | $226 | $58,62952 claims |
| AmgenOtezla | $108 | $55,23711 claims |
| GSKTrelegy Ellipta, Shingrix | $123 | $47,74075 claims |
| AbbVieLinzess, Creon | $543 | $31,95647 claims |
| PfizerEliquis | $306 | $26,77436 claims |
| AstraZenecaFarxiga | $69 | $10,44618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 adult health providers in Alabama.
Other adult health in Birmingham
- Lanier OhareBirmingham$42K
- Jessica WrightBirmingham$33K
- Sara HopperBirmingham$21K
- Andrea SuttonBirmingham$21K
- Laura RomundstadBirmingham$10K
- Jane DavisBirmingham$9K
- Anissa ThomasBirmingham$8K
- Chelsey KahlerBirmingham$5K
- Mary WadeBirmingham$5K
- Merry WoodsBirmingham$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.